Bethesda, Maryland 20892

  • Unspecified Childhood Solid Tumor, Protocol Specific


RATIONALE: New diagnostic procedures such as 1H-nuclear magnetic resonance spectroscopic imaging may be more effective than MRI in evaluating side effects of cancer therapy in patients who are receiving treatment for tumors. PURPOSE: Diagnostic trial using 1H-nuclear magnetic resonance spectroscopic imaging and MRI of the brain in patients who are receiving cancer therapy for tumors.

Study summary:

OBJECTIVES: - Determine the specific patterns of brain metabolites that are associated with therapy-related neurotoxicity using 1H-nuclear magnetic resonance spectroscopic imaging in patients with cancer. OUTLINE: Patients undergo 1H-nuclear magnetic resonance spectroscopic imaging (1H-NMRSI), followed by gadopentetate dimeglumine IV, followed by conventional magnetic resonance imaging (MRI) prior to anticancer therapy, immediately after the first course of therapy, prior to subsequent courses of therapy, and/or after completion of all therapy. Patients may also undergo age-appropriate neuropsychological testing within 1 week of 1H-NMRSI and conventional-contrast MRI. PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study within 2 years.


DISEASE CHARACTERISTICS: - Diagnosis of brain tumor OR - Receiving high-dose systemic chemotherapy, intrathecal chemotherapy (lumbar puncture or intra-Ommaya), or cranial radiotherapy OR - Documented or suspected clinical neurotoxicity presumed to be caused by anticancer treatment - No preexisting neurologic or genetic conditions unrelated to tumor PATIENT CHARACTERISTICS: Age: - Any age Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Other: - Not pregnant - Negative pregnancy test - No braces or permanent retainers - No metallic implant, including cardiac pacemakers, neural pacemakers, shrapnel, cochlear implants, or ferrous surgical clips - No physical or psychological factor that would preclude imaging studies - No history of severe reaction to gadolinium PRIOR CONCURRENT THERAPY: Biologic therapy: - Concurrent immunotherapy allowed Chemotherapy: - See Disease Characteristics - Concurrent chemotherapy allowed Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - Concurrent radiotherapy allowed Surgery: - Not specified



Primary Contact:

Study Chair
Katherine Warren, MD
NCI - Pediatric Oncology Branch

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.